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7T MRI in natalizumab-associated PML
and ongoing MS disease activity
A case study
ABSTRACT
Objective: To assess the ability of ultra-high-field MRI to distinguish early progressive multifocal
leukoencephalopathy (PML) from multiple sclerosis (MS) lesions in a rare case of simultaneous
presentation of natalizumab–associated PML and ongoing MS activity.
Methods: Advanced neuroimaging including 1.5T, 3T, and 7T MRI with a spatial resolution of up
to 0.08 mm3 was performed.
Results: 7T MRI differentiated between PML-related and MS-related brain damage in vivo. Ring-
enhancing MS plaques displayed a central vein, whereas confluent PML lesions were preceded by
punctate or milky way–like T2 lesions.
Conclusions: Given the importance of early diagnosis of treatment-associated PML, future sys-
tematic studies are warranted to assess the value of highly resolving MRI in differentiating
between early PML- and MS-induced brain parenchymal lesions. Neurol Neuroimmunol
Neuroinflamm 2015;2:e171; doi: 10.1212/NXI.0000000000000171
GLOSSARY
EDSS 5 Expanded Disability Status Scale; FLAIR 5 fluid-attenuated inversion recovery; IRIS 5 immune reconstitution
inflammatory syndrome;MR5magnetic resonance;MS 5multiple sclerosis; NAA5 N-acetylaspartate; NTZ5 natalizumab;
PML 5 progressive multifocal leukoencephalopathy; SWI 5 susceptibility-weighted imaging; T1W 5 T1-weighted; T2W 5
T2-weighted; TE 5 echo time; TI 5 inversion time; TR 5 repetition time.
One adverse effect of effective disease-modifying therapies of multiple sclerosis (MS) such as na-
talizumab (NTZ) is the development of progressive multifocal leukoencephalopathy (PML).1
However, identifying PML lesions at early stages remains difficult in daily clinical routine as
their presentation is often similar to that of MS plaques.2 NTZ-associated PML initially causes
subcortical or U-fiber lesions, which are also a hallmark of MS. On the other hand, large
edematous MS plaques can mimic expanding PML lesions. Moreover, CSF PCR testing for
JC virus DNA has recently been proven imperfect and can further delay PML diagnosis.3
We assessed the potential of ultra-high-field MRI at 7T with a spatial resolution of up to
0.08 mm3 to differentiate between early PML and MS-related brain damage in a case of simul-
taneous presentation of NTZ-associated PML, ongoing MS activity, and immune reconstitu-
tion inflammatory syndrome (IRIS).
METHODS Clinical investigations comprised detailed neurologic examination, MRI at 1.5T, 3T, and 7T, magnetic resonance (MR)
spectroscopy at 3T, and longitudinal CSF analysis. Additionally, blood samples were tested for neutralizing antibodies to NTZ.Written
informed consent was obtained from the patient for all procedures.
Image acquisition. Clinical routine MRI at 1.5T and 3T included T1-weighted (T1W), T2-weighted (T2W), fluid-attenuated
inversion recovery (FLAIR) or double inversion recovery, and diffusion-weighted imaging.
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7TMRI was performed using a whole-body MR scanner (Mag-
netom; Siemens, Erlangen, Germany) equipped with a 24-channel
receive head coil (Nova Medical, Wilmington, MA) and a birdcage
volume coil used for transmission. The imaging protocol (day 4)
included T2*W imaging (echo time [TE] 5 25.0 ms; repetition
time [TR]5 1600 ms; spatial resolution5 0.23 0.23 2.0 mm3
and 0.5 3 0.5 3 2.0 mm3), pregadolinium and postgadolinium
T1W magnetization-prepared rapid gradient echo (TE 5 2.98 ms;
TR5 2,300ms; inversion time [TI]5 900ms; spatial resolution5
1.0 3 1.0 3 1.0 mm3), FLAIR (TE 5 90 ms; TR 5 16,000 ms;
TI5 2,925.5 ms; spatial resolution5 1.03 1.03 3.0 mm3), 3D
gradient echo flow-compensated susceptibility-weighted imaging
(SWI; TE 5 14 ms; TR 5 25 ms; spatial resolution 5 0.5 3
0.5 3 1.0 mm3), and pregadolinium and postgadolinium T1W
volumetric interpolated brain examination.
3T single volume MR spectroscopy was performed using
a point resolved spectroscopy sequence (volume of interest 5
20 3 20 3 20 mm3, TR/TE 5 3,000/30 ms, number of
averages 5 128, acquisition time 5 1,024 ms).
The lesion morphology was subjectively analyzed by a sin-
gle rater who was not blinded to the diagnosis. A milky
way–like lesion was defined as a small lesion on T2*W
images (day 4, spatial resolution 5 0.2 3 0.2 3 2.0 mm3),
typically ,3 mm in diameter, within a region of dirty white
matter, that clearly shows PML development on a follow-up
MRI. Hyperintensities within an extensive PML lesion that
were not clearly distinguishable from each other were excluded.
Milky way–like lesions were counted on the 7T T2*W images
(day 4) with the highest available spatial resolution (0.2 3
0.2 3 2.0 mm3).
CASE REPORT A 47-year-old man had been
diagnosed with relapsing-remitting MS in 2010. After
switching from interferon b-1a to NTZ, previous
clinical and MRI disease activity ceased and twice-
yearly MRI did not show any evidence of disease
activity until the 37th infusion. Within 3 days after
the 37th administration of NTZ, cognitive deficits,
uncontrolled emotional expressions, disorientation,
and inappropriate behavior developed rapidly. Figure 1
Figure 1 Detailed overview of treatment course and paraclinical findings
Maximum intensity projection maps of supratentorial inversion recovery images show quickly progressing right frontoparietal and cerebellar progressive mul-
tifocal leukoencephalopathy (PML) lesions. Perilesional contrast enhancement consistent with immune reconstitution inflammatory syndromewas detectable at
the edges of the PML lesions in the bilateral frontal lobe and ceased after initiation of high-dose corticosteroid treatment (white arrows). These PML lesions did
not expand over time (white ovals). Note the differences between the lesion contrast enhancement patterns on the 7T maximum intensity projection map that
visualizes both ring-enhancing multiple sclerosis lesions (red arrows) and punctate PML lesions (white asterisks). NTZ 5 natalizumab. Supratentorial imaging:
Maximum intensity projection map of five 3T fluid-attenuated inversion recovery (FLAIR) images and maximum intensity projection map of 4 1.5T double
inversion recovery (DIR) images with a slice thickness of 4 mm are presented. Infratentorial imaging: 3T FLAIR and 1.5T DIR images are presented. GDTPA-
enhanced imaging: A maximum intensity projection map of 7T GDTPA-enhanced volumetric interpolated brain examination (VIBE) images, 7T GDTPA-enhanced
VIBE images, 3T GDTPA-enhanced T1-weighted images, and 1.5T GDTPA-enhanced T1-weighted images are presented.
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provides a detailed overview of the treatment course and
paraclinical findings.
In the initial 1.5T MRI on day 1 immediately
after referral to our department we observed PML-
suspicious confluent lesions in the cerebellum and
the supratentorial bilateral frontal and parietal white
matter (figures 1 and 2A). Due to suspected PML,
NTZ was discontinued and 5 cycles of plasma
exchange started (day 1). PCR testing of CSF was
positive for JC virus (155 copies per milliliter), and
the Expanded Disability Status Scale (EDSS) score
was 4.5.
7T MRI was performed on day 4. The time lapse
between the initial scans at 1.5T and at 7T was caused
by organizational issues and may limit a comparison
between these 2 scans especially regarding the pat-
terns of contrast enhancement. 7T MRI on day 4
revealed different patterns of brain parenchymal dam-
age. First, diffuse rim-like, perilesional contrast
enhancement atypical of MS was observed around
some PML-suspicious confluent lesions in the bilat-
eral frontoparietal white matter (figure 1). These
changes were presumably related to IRIS. Second,
5 ring-enhancing lesions were observed in the right
periventricular white matter (figure 2D). Each
of these lesions was characterized by a central vein
(figure 2C, white arrows) and mild perifocal edema
(7T T2*; figure 2C, black asterisks), and one lesion
presented signal loss on SWI, e.g., resulting from
central iron deposits or severe demyelination. These
ring-enhancing lesions were classified as acute MS
lesions in accordance with previous reports on char-
acteristic MS lesion morphology imaged by 7T
MRI.4–6
Finally, 567 small punctate or milky way–like
lesions3 were visualized predominantly in the right
centrum semiovale on high-resolution 7T T2W
images (figure 2C; figure 3, oval). Of these, only
173 lesions (31%) exhibited a central vein at an ultra-
high in-plane resolution of 0.2 3 0.2 mm2 that was
Figure 2 7T MRI can differentiate between early PML and MS lesions
Two different patterns of brain lesions were observed using 7T MRI: ring-enhancing lesions (black arrows, D) reveal central
intralesional veins characteristic for multiple sclerosis (MS) plaques (white arrows, C) and perilesional edema (black aster-
isks, C) on T2*-weighted imaging. Additionally, small punctate lesions (oval, C) were present on T2*-weighted imaging. These
microcystic lesions developed into confluent progressive multifocal leukoencephalopathy (PML) lesions over time (E), and
may thus represent earliest PML stages. In contrast, punctate lesions were barely visible on the initial 1.5T T2-weighted
images on day 1 (A). Volumetric interpolated brain examination (VIBE)–gad: GDTPA-enhanced 7T VIBE. (A, B) 1.5T MRI (day
1). (C, D) 7T MRI (day 4). (E) 3T fluid-attenuated inversion recovery (day 24).
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much smaller than a typical vein within the center of
an MS lesion. Contrast-enhanced 7T T1W imaging
showed corresponding areas of punctate contrast
enhancement that were not fully detectable in the
initial MRI scans at 1.5T (figure 2).
Due to suspected IRIS, we administered cortico-
steroid pulse therapy on day 4 when the patient pre-
sented with clinical worsening.
7T and 3T MRI on day 11 visualized decreasing
perilesional IRIS-like contrast enhancement. Nota-
bly, the size of these contrast-enhancing PML lesions,
which had probably been recognized by the immune
system, remained stable, whereas PML lesions with-
out peripheral contrast enhancement expanded signif-
icantly (figure 1). Accordingly, some of these PML
lesions presented with restricted diffusion at their
edges (data not shown) as revealed by 3TMRI, which
has been suggested as a sign of ongoing PML.2,7,8
In response, we initiated antiviral therapy (mirta-
zapine, mefloquine, ribavirin, amantadine),1 but clin-
ical symptoms worsened (EDSS 8.5), and the patient
developed complex partial seizures. Concurrently,
PCR on CSF revealed a high number of JC virus
DNA copies (7,186 copies per milliliter), and the
JC virus antibody index was 5.43 on day 19.
Next, 7T MRI and 3T MRI including proton
spectroscopy were performed on day 24. As expected,
contrast enhancement of all ring-enhancing MS
lesions ceased after high-dose corticosteroid therapy,
and the MS lesion size remained stable, whereas
PML lesions continued to grow centrifugally
(figure 1). Notably, punctate or milky way–like
lesions that were detectable on the initial 7T MRI
in the right hemisphere had amalgamated into one
large, confluent PML lesion during corticosteroid
therapy (figure 2E). Proton spectroscopy in a PML
lesion and an exemplary MS lesion of almost the
same age (figure e-1 at Neurology.org/nn) revealed
significantly reduced N-acetylaspartate (NAA), cho-
line, and creatine levels and elevated lipids in the center
of the PML lesion indicating ongoing necrosis. In con-
trast, the MS lesion presented with only moderately
decreased levels of NAA. Hence, PML may cause
destructive brain tissue damage much more rapidly
than MS-related inflammation.
MRI follow-up (1.5T) at day 34 did not reveal
new or enlarging PML lesions (figure 1), clinical
symptoms began to improve (EDSS 6.0), and JC
virus DNA in CSF decreased to 828 copies per
milliliter. Neutralizing antibodies against NTZ were
not detectable.
DISCUSSION In this rare case of simultaneous
NTZ-associated PML, IRIS, and MS relapse, 7T MRI
yielded 2 main findings. First, high-resolution T2*W
imaging distinguished between MS and PML brain
lesions by the presence or absence of a characteristic
central intralesional vein, which is a hallmark of
MS,4–6 but only rarely detectable in lesions of other
origin (e.g., neuromyelitis optica,4 Susac syndrome,5
asymptomatic white matter lesions6). In our case, a
central vessel was only infrequently visualized within
milky way–like PML lesions, and these vessels were
much smaller than the veins that are typically
observable within MS lesions. Quantification of the
milky way lesion count was potentially influenced by
(1) a misclassification of small MS lesions or
Virchow-Robin spaces as milky way lesions, (2)
motion artifacts, or (3) a small gap between the
superior and the inferior T2*W image acquisition.
Second, punctate or microcystic lesions were dis-
tinctly visualized at 7T on day 4, however, not fully
detectable on the initial 1.5T MRI scans. Some of
these milky way–like lesions were associated with
simultaneous gadolinium enhancement. During
follow-up, these lesions rapidly formed large conflu-
ent plaques characteristic for PML. The interpreta-
tion of these findings remains highly speculative.7–9
On the one hand, punctate gadolinium-enhancing
lesion pattern has been associated with IRIS, suggest-
ing that these alterations highlight an overwhelming
immune response, presumably within perivascular
spaces.8 On the other hand, punctate or milky way–
like lesions have also been described as an early man-
ifestation of PML, indicating areas of active JC virus
replication.9 Our own observations support the
hypothesis of ongoing JC virus replication in punc-
tate lesions since high-dose corticosteroid treatment
triggered punctate lesion evolution, and increased
CSF JC virus load up to 40-fold. The increase in
Figure 3 Punctate PML lesions visualized by highly resolving T2*-weighted
imaging at 7T (day 4)
7T T2*-weighted images delineate even miniscule punctate lesions in early progressive multi-
focal leukoencephalopathy (PML). Although the lesion distribution pattern was principally per-
ivascular in appearance (oval) an intralesional central vein was not generally detectable in these
microcystic PML lesions despite ultrahigh spatial resolution. Sequence parameters: echo time5
25.0 ms; repetition time 5 1,600 ms; spatial resolution 5 (0.2 3 0.2 3 2.0) mm3.
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JC virus load is, however, also explicable by plasma
exchange, as reported recently.10
An early diagnosis of treatment-associated PML is
crucial. Our case study emphasizes the need for future
studies investigating the value of high-resolution MRI
to differentiate early PML from MS-associated brain
parenchymal lesions.
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